Glibclay 1.5 Tablet contains Glibenclamide 1.5mg, a well-established sulfonylurea oral antidiabetic agent used for effective glycemic control in patients with type 2 diabetes mellitus. It works by stimulating insulin release from pancreatic beta cells, helping to reduce elevated blood glucose levels.
This low-dose formulation is particularly suitable for patients requiring gradual glucose control or dose titration as part of individualized diabetes management plans. It supports consistent blood sugar regulation when combined with proper diet, exercise, and medical supervision.
Glibenclamide tablets are widely prescribed in general medicine clinics, diabetic care centers, and multispecialty hospitals. Their long-standing clinical trust ensures continuous demand across retail pharmacies and institutional healthcare setups.
Adding Glibclay 1.5 Tablet to your diabetes and metabolic-care segment strengthens your product portfolio, creating opportunities in pharmacy distribution, hospital supplies, institutional procurement, export markets, and third-party manufacturing. Its reliability and routine prescription make it a commercially strong antidiabetic product.